--- title: "Retatrutide | PepTracker Pro" url: https://peptrackerpro.com/peptides/retatrutide description: "An investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) **Research-only content.** This page is for educational purposes and does not constitute medical advice. Read full disclaimer → (https://peptrackerpro.com/research-disclaimer) # Retatrutide High Evidence An investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease. Aliases LY3437943 +1 more Evidence High Evidence Last Updated 2026-06-13 Reading Time 4 min ## What It Is Retatrutide (LY3437943) is an investigational triple incretin agonist targeting GIP, GLP-1, and glucagon receptors simultaneously, developed by Eli Lilly. It is the first triple agonist to reach Phase 3 development and has produced the highest weight loss of any GLP-1-class therapy tested to date. In the Phase 3 TRIUMPH-4 trial (December 2025), retatrutide achieved 28.7% mean body weight loss at 68 weeks on the 12 mg dose — participants lost an average of 71.2 lbs (32.3 kg) from a baseline of 248.5 lbs, with 58.6% achieving ≥25% total body weight loss. Beyond weight, retatrutide reduced WOMAC knee pain scores by 75.8%, with more than 1 in 8 patients becoming completely pain-free — the first successful Phase 3 demonstrating weight-loss-mediated joint pain improvement. In March 2026, the TRANSCEND-T2D-1 trial reported A1C reductions of up to 2.0% and weight loss of up to 36.6 lbs (16.8%) at 40 weeks in type 2 diabetes patients. The TRIUMPH Phase 3 program includes eight clinical trials evaluating retatrutide in general obesity, type 2 diabetes, obstructive sleep apnea, and knee osteoarthritis. On May 21, 2026, Eli Lilly announced positive topline data from TRIUMPH-1, the pivotal 80-week general obesity trial: participants on the 12 mg dose lost an average of 28.3% of their body weight at 80 weeks, with all three doses (4 mg, 9 mg, and 12 mg) meeting primary and key secondary endpoints. Among participants with a starting BMI of 35 or higher who continued on the drug, weight loss reached up to 30.3% at 104 weeks. These results form the primary basis for the planned NDA submission. A notable safety signal is dysesthesia (abnormal skin sensation), reported in 8.8% (9 mg) and 20.9% (12 mg) of patients vs 0.7% on placebo, and higher discontinuation rates (18.2%) compared to competitors. Eli Lilly plans to file the NDA in Q4 2026, with a potential FDA decision by mid-to-late 2027. The pivotal TRIUMPH-1 trial — the largest in the program at 80 weeks in adults with obesity/overweight without T2D — is the registration study for the weight-management NDA. The TRIUMPH-1 results confirm retatrutide as the highest-efficacy weight-loss compound in clinical development, with additional Phase 3 readouts for type 2 diabetes, cardiovascular disease, and other indications expected through Q3–Q4 2026. Seven additional Phase III readouts are expected throughout 2026, and the overall TRIUMPH program encompasses eight pivotal trials enrolling more than 5,800 participants plus a separate roughly 10,000-patient cardiovascular outcomes trial (TRANSCEND-CV). TRIUMPH-1 secondary biomarker endpoints showed statistically significant improvements across waist circumference, non-HDL cholesterol, triglycerides, systolic blood pressure, and high-sensitivity C-reactive protein at 80 weeks across all dose groups, though the trial was not powered for cardiovascular event outcomes. At the ADA 2026 Scientific Sessions (June 5–8, New Orleans), Eli Lilly is presenting full TRIUMPH-1 data with complete secondary biomarker endpoints, and TRANSCEND-T2D-1 full data for type 2 diabetes. These presentations represent the first comprehensive peer-reviewed disclosure of the pivotal registration data underpinning the planned Q4 2026 NDA submission. At the ADA 2026 Scientific Sessions (June 7, New Orleans), Eli Lilly presented full data from TRIUMPH-4, the first Phase 3 trial evaluating a pharmacotherapy in adults with both obesity/overweight and knee osteoarthritis. TRIUMPH-4 met all primary and key secondary endpoints at 68 weeks. Participants receiving retatrutide 12 mg achieved 28.7% mean body weight loss (vs 3.3% placebo) — the highest weight loss figure across all retatrutide Phase 3 trials to date — alongside a 75.8% reduction in WOMAC knee pain scores (4.5-point reduction vs 0.5-point placebo). At 68 weeks, 12.0% of the 12 mg group were completely free of knee pain compared with 4.2% in the placebo group. Participants also experienced a 14 mmHg reduction in systolic blood pressure and significant improvements in physical function. The average weight loss of 71.2 lbs in the TRIUMPH-4 12 mg arm represents the highest absolute weight reduction reported in any retatrutide trial to date. These data support a potential sNDA or supplemental indication for musculoskeletal comorbidities alongside the obesity NDA filing planned for Q4 2026. Also known as: LY3437943, Triple G ## Regulatory Status Investigational — Phase 3 (positive pivotal data) TRIUMPH-1 pivotal 80-week obesity trial reported positive topline data May 21, 2026: 28.3% weight loss at 12 mg dose, all doses met endpoints. Up to 30.3% at 104 weeks in BMI ≥35 subgroup. TRIUMPH-4 (obesity + OA, 28.7% at 68 weeks) and TRANSCEND-T2D-1 (T2D, A1C -2.0%) both positive. NDA filing planned Q4 2026. FDA decision expected mid-to-late 2027. Effective: May 2026 View FDA Source (https://investor.lilly.com/news-releases/news-release-details/lillys-retatrutide-delivered-clinically-meaningful-weight-loss) ## Evidence Snapshot High Evidence Low Medium High | Study Type | Model | Outcome | Link | | --- | --- | --- | --- | | Phase 2 | Triple agonist (GIP/GLP-1/glucagon) in adults with obesity | Up to 24% weight loss over 48 weeks | Source: https://pubmed.ncbi.nlm.nih.gov/37351564/ | | Phase 3 (TRIUMPH-4) | Adults with obesity and knee osteoarthritis (12 mg dose, 68 weeks) | 28.7% mean weight loss; 75.8% reduction in WOMAC knee pain; >12.5% completely pain-free | Source: https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average | | Phase 3 (TRANSCEND-T2D-1) | Adults with type 2 diabetes, 40 weeks | A1C reductions of up to 2.0%; weight loss of up to 36.6 lbs (16.8%) | Source: https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-demonstrated-significant-reductions-in-a1c-and-weight-in-first-phase-3-trial-for-treatment-of-type-2-diabetes-302718589.html | | Phase 3 (TRIUMPH) | Retatrutide in obesity with osteoarthritis | Average 71.2 lbs weight loss with substantial osteoarthritis pain relief — first successful Phase 3 for weight-loss-mediated joint improvement | Source: https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average | | Phase 3 (TRIUMPH-1) | Adults with obesity/overweight without T2D, 80 weeks (pivotal registrational trial) | 28.3% mean weight loss at 12 mg dose; up to 30.3% at 104 weeks in BMI ≥35 subgroup; all doses met primary and key secondary endpoints | Source: https://investor.lilly.com/news-releases/news-release-details/lillys-retatrutide-delivered-clinically-meaningful-weight-loss | | Phase 3 (TRIUMPH-1 + TRANSCEND-T2D-1 — ADA 2026 full data) | Full data presentations at ADA 2026 Scientific Sessions (June 5–8, 2026): TRIUMPH-1 complete secondary endpoints and TRANSCEND-T2D-1 T2D data | TRIUMPH-1: 28.3% weight loss (12 mg, 80 wks); significant improvements in waist circumference, non-HDL cholesterol, triglycerides, SBP, and hsCRP. TRANSCEND-T2D-1: A1C −2.0%, weight −16.8% at 40 wks. Dysesthesia in 20.9% at 12 mg (vs 0.7% placebo) confirmed as key differentiated safety signal. | Source: https://investor.lilly.com/news-releases/news-release-details/lillys-retatrutide-delivered-clinically-meaningful-weight-loss | | Phase 3 (TRIUMPH-4 — ADA 2026, June 7) | Adults with obesity/overweight and knee osteoarthritis — 68-week, randomized, double-blind, placebo-controlled | 12 mg: 28.7% weight loss (71.2 lbs avg) vs 3.3% placebo; WOMAC knee pain −75.8% (4.5 pts vs 0.5 pts placebo); 12% completely pain-free vs 4.2% placebo; systolic BP −14 mmHg; all primary and key secondary endpoints met | Source: https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average | ## Commonly Discussed Benefits Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss Researching Retatrutide? Track it, set reminders, and keep notes in the free app. Track in App (https://app.peptrackerpro.com/?add=retatrutide) ## Safety & Cautions - Still in clinical trials; NDA filing planned Q4 2026, FDA decision expected mid-to-late 2027 - Dysesthesia (abnormal skin sensation) reported in 8.8% (9 mg) and 20.9% (12 mg) vs 0.7% placebo - Higher discontinuation rates (18.2%) compared to other GLP-1 class therapies - Gastrointestinal side effects common in trials - Long-term safety data beyond 104 weeks not yet available - Only available through clinical trial enrollment until potential approval ## Comparisons See how Retatrutide compares to related peptides: Retatrutide vs Amycretin: https://peptrackerpro.com/compare/retatrutide-vs-amycretin Retatrutide vs CagriSema: https://peptrackerpro.com/compare/retatrutide-vs-cagrisema Retatrutide vs CT-388: https://peptrackerpro.com/compare/retatrutide-vs-ct-388 Retatrutide vs Efocipegtrutide: https://peptrackerpro.com/compare/retatrutide-vs-efocipegtrutide Retatrutide vs Efpeglenatide: https://peptrackerpro.com/compare/retatrutide-vs-efpeglenatide Retatrutide vs GLP-1-GIP-Lani (Quintuple Agonist): https://peptrackerpro.com/compare/retatrutide-vs-glp1-gip-lani Retatrutide vs Maridebart Cafraglutide (MariTide): https://peptrackerpro.com/compare/retatrutide-vs-maridebart-cafraglutide Retatrutide vs MariTide: https://peptrackerpro.com/compare/retatrutide-vs-maritide Retatrutide vs Mazdutide: https://peptrackerpro.com/compare/retatrutide-vs-mazdutide Retatrutide vs NA-931 (Bioglutide): https://peptrackerpro.com/compare/retatrutide-vs-na-931 Retatrutide vs Pep19: https://peptrackerpro.com/compare/retatrutide-vs-pep19 Retatrutide vs Semaglutide: https://peptrackerpro.com/compare/retatrutide-vs-semaglutide Retatrutide vs Survodutide: https://peptrackerpro.com/compare/retatrutide-vs-survodutide Retatrutide vs Tirzepatide: https://peptrackerpro.com/compare/retatrutide-vs-tirzepatide Retatrutide vs UBT251: https://peptrackerpro.com/compare/retatrutide-vs-ubt251 Retatrutide vs WVE-007: https://peptrackerpro.com/compare/retatrutide-vs-wve-007 Retatrutide vs ARO-INHBE: https://peptrackerpro.com/compare/retatrutide-vs-aro-inhbe Retatrutide vs HRS9531 (KAI-9531): https://peptrackerpro.com/compare/retatrutide-vs-hrs9531 ## Calculator Tools Use our research tools to explore dosing and reconstitution data: Reconstitution Calculator: https://peptrackerpro.com/calculators ## Citations 1. [1] Jastreboff AM. et al. — Triple-hormone-receptor agonist retatrutide for obesity. N Engl J Med. 2023 PubMed (https://pubmed.ncbi.nlm.nih.gov/37351564/) 2. [2] Eli Lilly — TRIUMPH-4 Phase 3 results, December 2025 PubMed (https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average) 3. [3] Eli Lilly — TRANSCEND-T2D-1 Phase 3 topline results, March 2026 PubMed (https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-demonstrated-significant-reductions-in-a1c-and-weight-in-first-phase-3-trial-for-treatment-of-type-2-diabetes-302718589.html) 4. [4] Giblin MJ. et al. — TRIUMPH registrational clinical trials design: obesity, OSA, and knee OA. Diabetes Obes Metab. 2026 PubMed (https://dom-pubs.onlinelibrary.wiley.com/doi/full/10.1111/dom.70209) 5. [5] Eli Lilly — TRIUMPH-1 Phase 3 topline results (28.3% weight loss at 80 weeks), May 21, 2026 PubMed (https://investor.lilly.com/news-releases/news-release-details/lillys-retatrutide-delivered-clinically-meaningful-weight-loss) 6. [6] Eli Lilly — Retatrutide TRIUMPH-1 and TRANSCEND-T2D-1 full data at ADA 2026 Scientific Sessions. June 2026 PubMed (https://www.ajmc.com/view/retatrutide-achieves-up-to-30-3-average-weight-loss-in-phase-3-triumph-1-trial) 7. [7] Lilly — TRIUMPH-4: Retatrutide Delivers Weight Loss and Osteoarthritis Pain Relief, ADA 2026 PubMed (https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average) 8. [8] TRIUMPH-4: Retatrutide Achieves 28.7% Weight Loss and Marked Knee Pain Reduction — Patient Care Online PubMed (https://www.patientcareonline.com/view/retatrutide-achieves-up-to-28-7-weight-loss-and-marked-knee-pain-reduction-in-phase-3-triumph-4-trial) ### Keep researching in the app - Log Retatrutide to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack Open PepTracker Pro Free: https://app.peptrackerpro.com/?add=retatrutide Browse more peptides: https://peptrackerpro.com/peptides ## Related Peptides ### Amycretin Medium Evidence A unimolecular GLP-1 and amylin receptor dual agonist in Phase 3 trials, available in both subcutaneous and oral formulations, with up to 22% weight loss in Phase 1b/2a. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)+1 more View Details: https://peptrackerpro.com/peptides/amycretin \+ Compare: https://peptrackerpro.com/compare?select=amycretin Track in App: https://app.peptrackerpro.com/?add=amycretin ### CagriSema High Evidence A fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) studied for enhanced weight loss through dual hormonal pathways. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Fat Loss: https://peptrackerpro.com/benefits/fat-loss Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/cagrisema \+ Compare: https://peptrackerpro.com/compare?select=cagrisema Track in App: https://app.peptrackerpro.com/?add=cagrisema ### CT-388 Medium Evidence An investigational once-weekly subcutaneous dual GLP-1 and GIP receptor agonist from Roche/Genentech (acquired with Carmot Therapeutics for ~$2.7 billion; Roche code RO7795068). CT-388 is engineered as a 'signal-biased' agonist: it potently activates both incretin receptors but recruits little or no beta-arrestin, which is expected to reduce receptor internalization and desensitization and thereby prolong pharmacological activity. In a Phase 1b study it produced ~18.8% placebo-adjusted weight loss at 24 weeks, and in the Phase 2 CT388-103 dose-finding trial (469 adults with obesity/overweight) it delivered a placebo-adjusted mean weight loss of 22.5% at 48 weeks (efficacy estimand; 18.3% treatment-regimen estimand) at the top 24 mg dose, without reaching a plateau. Roche advanced CT-388 into Phase 3 in the first half of 2026, positioning it as a late-entrant competitor to tirzepatide (Zepbound) with a potentially differentiated biased-signaling mechanism. Weight Management: https://peptrackerpro.com/benefits/weight-management Glycemic Control: https://peptrackerpro.com/benefits/glycemic-control View Details: https://peptrackerpro.com/peptides/ct-388 \+ Compare: https://peptrackerpro.com/compare?select=ct-388 Track in App: https://app.peptrackerpro.com/?add=ct-388 ### Efocipegtrutide Medium Evidence Efocipegtrutide (Hanmi code HM15211) is an investigational, long-acting, once-weekly GLP-1/GIP/glucagon 'triple' receptor agonist being developed primarily for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) rather than obesity alone. It is built on Hanmi's LAPSCovery platform as a chemical conjugate of a chimeric tri-agonist peptide (TA15211) fused to a human IgG4 Fc fragment, which extends its half-life via FcRn-mediated recycling and enables weekly subcutaneous dosing. By adding glucagon-receptor activation to the GLP-1/GIP dual mechanism, efocipegtrutide is designed to combine appetite suppression and glycemic control with increased energy expenditure and direct hepatic anti-steatotic, anti-inflammatory, and anti-fibrotic effects. In a Phase 1b/2a study in obese subjects with non-alcoholic fatty liver disease, 12 weeks of treatment reduced liver fat by roughly 20% to 59% (dose-dependent, MRI-PDFF) versus about 6% on placebo. It has FDA Fast Track designation for MASH and orphan-drug designations from the FDA and EMA for primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and idiopathic pulmonary fibrosis (IPF). The 52-week adaptive Phase 2 HM-TRIA-201 study (NCT04505436) in biopsy-confirmed MASH with fibrosis is the pivotal read the field is watching. Liver Health: https://peptrackerpro.com/benefits/liver-health Weight Management: https://peptrackerpro.com/benefits/weight-management Glycemic Control: https://peptrackerpro.com/benefits/glycemic-control Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/efocipegtrutide \+ Compare: https://peptrackerpro.com/compare?select=efocipegtrutide Track in App: https://app.peptrackerpro.com/?add=efocipegtrutide ### Efpeglenatide High Evidence A once-weekly, long-acting GLP-1 receptor agonist from Hanmi Pharmaceutical built on a different molecular backbone than semaglutide or liraglutide: instead of a modified human GLP-1, efpeglenatide uses exendin-4 - the naturally DPP-4-resistant GLP-1 mimic first found in Gila monster venom - fused to a fragment of a human antibody (an IgG4 Fc) through a small polyethylene-glycol (mini-PEG) linker using Hanmi's LAPSCOVERY half-life-extension platform. That design lets one subcutaneous injection lower blood sugar, curb appetite and reduce body weight for a full week. Efpeglenatide is best known for the landmark AMPLITUDE-O cardiovascular outcomes trial (NEJM 2021), in which 4,076 people with type 2 diabetes and cardiovascular or kidney disease had a 27% lower rate of major adverse cardiovascular events (MACE hazard ratio 0.73) and a 32% lower rate of a composite kidney outcome (hazard ratio 0.68) versus placebo - the first cardiovascular outcomes win for an exendin-based GLP-1 and one of the clearest kidney signals in the class, with benefit seen regardless of whether patients were also taking an SGLT2 inhibitor. Originally licensed to Sanofi and then returned to Hanmi in 2020, efpeglenatide is now being advanced primarily for obesity and overweight, with a Phase 3 program that has completed enrollment and a targeted first launch in South Korea in the second half of 2026. It is an investigational (not yet approved) prescription medicine, not a supplement or research chemical. Weight Management: https://peptrackerpro.com/benefits/weight-management Glycemic Control: https://peptrackerpro.com/benefits/glycemic-control Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular Kidney Health: https://peptrackerpro.com/benefits/kidney-health View Details: https://peptrackerpro.com/peptides/efpeglenatide \+ Compare: https://peptrackerpro.com/compare?select=efpeglenatide Track in App: https://app.peptrackerpro.com/?add=efpeglenatide ### GLP-1-GIP-Lani (Quintuple Agonist) Low Evidence A first-in-class peptide-drug conjugate that simultaneously activates five metabolic receptors (GLP-1R, GIPR, PPARα, PPARγ, PPARδ), published in Nature in April 2026 with preclinical results surpassing tirzepatide and triple agonists. Weight Management: https://peptrackerpro.com/benefits/weight-management Fat Loss: https://peptrackerpro.com/benefits/fat-loss Metabolism: https://peptrackerpro.com/benefits/metabolism Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation View Details: https://peptrackerpro.com/peptides/glp1-gip-lani \+ Compare: https://peptrackerpro.com/compare?select=glp1-gip-lani Track in App: https://app.peptrackerpro.com/?add=glp1-gip-lani ### Maridebart Cafraglutide (MariTide) Medium Evidence Amgen's once-monthly injectable GIP receptor antagonist and GLP-1 receptor agonist, showing up to 20% weight loss in phase 2 trials with a unique mechanism that blocks GIP while activating GLP-1. Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Fat Loss: https://peptrackerpro.com/benefits/fat-loss View Details: https://peptrackerpro.com/peptides/maridebart-cafraglutide \+ Compare: https://peptrackerpro.com/compare?select=maridebart-cafraglutide Track in App: https://app.peptrackerpro.com/?add=maridebart-cafraglutide ### MariTide High Evidence A bispecific GIPR antagonist and GLP-1 receptor agonist antibody-peptide conjugate developed by Amgen for obesity and type 2 diabetes. View Details: https://peptrackerpro.com/peptides/maritide \+ Compare: https://peptrackerpro.com/compare?select=maritide Track in App: https://app.peptrackerpro.com/?add=maritide ### Mazdutide High Evidence The first dual GCG/GLP-1 receptor agonist approved in China for obesity and T2D, with Phase 3 showing up to 20.1% weight loss at the 9 mg dose and superiority over semaglutide. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/mazdutide \+ Compare: https://peptrackerpro.com/compare?select=mazdutide Track in App: https://app.peptrackerpro.com/?add=mazdutide ### NA-931 (Bioglutide) Medium Evidence The first oral quadruple receptor agonist targeting IGF-1, GLP-1, GIP, and glucagon receptors for obesity treatment with muscle preservation. Weight Management (https://peptrackerpro.com/benefits/weight-management)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Muscle Preservation (https://peptrackerpro.com/benefits/muscle-preservation)Metabolism (https://peptrackerpro.com/benefits/metabolism)+1 more View Details: https://peptrackerpro.com/peptides/na-931 \+ Compare: https://peptrackerpro.com/compare?select=na-931 Track in App: https://app.peptrackerpro.com/?add=na-931 ### Pep19 Low Evidence An orally dosed synthetic intracellular peptide that acts on the endocannabinoid system; an early human trial showed reduced visceral fat and improved sleep without lean-mass loss. Fat Loss: https://peptrackerpro.com/benefits/fat-loss Metabolism: https://peptrackerpro.com/benefits/metabolism Sleep: https://peptrackerpro.com/benefits/sleep View Details: https://peptrackerpro.com/peptides/pep19 \+ Compare: https://peptrackerpro.com/compare?select=pep19 Track in App: https://app.peptrackerpro.com/?add=pep19 ### Semaglutide High Evidence A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)+3 more View Details: https://peptrackerpro.com/peptides/semaglutide \+ Compare: https://peptrackerpro.com/compare?select=semaglutide Track in App: https://app.peptrackerpro.com/?add=semaglutide ### Survodutide Medium Evidence A dual GLP-1/glucagon receptor agonist with FDA Breakthrough Therapy designation for MASH and Priority Review NDA filed February 2026. Phase 3 SYNCHRONIZE-1 reported 16.6% weight loss at 76 weeks; approval possible Q3 2026. View Details: https://peptrackerpro.com/peptides/survodutide \+ Compare: https://peptrackerpro.com/compare?select=survodutide Track in App: https://app.peptrackerpro.com/?add=survodutide ### Tirzepatide High Evidence A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis. View Details: https://peptrackerpro.com/peptides/tirzepatide \+ Compare: https://peptrackerpro.com/compare?select=tirzepatide Track in App: https://app.peptrackerpro.com/?add=tirzepatide ### UBT251 Medium Evidence A GLP-1/GIP/glucagon triple receptor agonist in Phase 2 development for type 2 diabetes and obesity, competing with retatrutide in the triple-agonist space. View Details: https://peptrackerpro.com/peptides/ubt251 \+ Compare: https://peptrackerpro.com/compare?select=ubt251 Track in App: https://app.peptrackerpro.com/?add=ubt251 ### WVE-007 Low Evidence WVE-007 is Wave Life Sciences' investigational GalNAc-conjugated siRNA that silences the liver gene INHBE to lower the hepatokine Activin E, aiming to produce muscle-sparing fat loss. In the Phase 1 INLIGHT trial a single subcutaneous dose reduced visceral and total fat while preserving or increasing lean mass, with durable target knockdown that could support once- or twice-yearly dosing. Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss Muscle Preservation: https://peptrackerpro.com/benefits/muscle-preservation View Details: https://peptrackerpro.com/peptides/wve-007 \+ Compare: https://peptrackerpro.com/compare?select=wve-007 Track in App: https://app.peptrackerpro.com/?add=wve-007 ### ARO-INHBE Low Evidence An investigational RNA-interference (RNAi) therapeutic from Arrowhead Pharmaceuticals designed to treat obesity by silencing a fat-storage gene in the liver. ARO-INHBE is a GalNAc-conjugated small interfering RNA (siRNA) that reduces hepatic expression of the INHBE gene and its secreted product, the hepatokine Activin E. INHBE is a genetically validated target: people who naturally carry rare loss-of-function variants in INHBE have a healthier (less abdominal) fat distribution and a lower risk of type 2 diabetes, suggesting that lowering Activin E with a drug could reproduce that protective metabolic profile. In an ongoing Phase 1/2a trial (AROINHBE-1001, NCT06700538), a single subcutaneous dose reduced serum Activin E by up to about 94%, and monotherapy reduced visceral fat by roughly 10-16% while modestly increasing lean tissue. Most strikingly, when added to the incretin drug tirzepatide in obese patients with type 2 diabetes, ARO-INHBE roughly doubled weight loss (-9.4% versus -4.8% at week 16) and roughly tripled reductions in visceral, total, and liver fat versus tirzepatide alone. These are small, early, interim results (as few as 3-4 participants per combination arm) - not proof of durable or long-term benefit. ARO-INHBE is investigational, is not approved anywhere, and is not a supplement or research chemical; it is studied only in clinical trials. Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Body Composition (https://peptrackerpro.com/benefits/body-composition)Weight Management (https://peptrackerpro.com/benefits/weight-management)Metabolism (https://peptrackerpro.com/benefits/metabolism)+1 more View Details: https://peptrackerpro.com/peptides/aro-inhbe \+ Compare: https://peptrackerpro.com/compare?select=aro-inhbe Track in App: https://app.peptrackerpro.com/?add=aro-inhbe ### HRS9531 (KAI-9531) Medium Evidence An investigational once-weekly injectable dual GLP-1/GIP receptor agonist - the same peptide class as tirzepatide (Zepbound/Mounjaro) - developed by China's Jiangsu Hengrui Pharmaceuticals as HRS9531 and licensed to U.S.-based Kailera Therapeutics, which is developing it globally (outside Greater China) as KAI-9531. In the pivotal 48-week Phase 3 GEMINI-1 trial in China (NCT06396429; 567 adults with obesity or overweight without diabetes), once-weekly HRS9531 produced mean weight loss of about 17.4-19.2% at the 4 mg and 6 mg doses (per-protocol/hypothetical estimand) versus roughly 1.4% for placebo, with about 44% of 6 mg patients losing at least 20% of body weight and broad improvements in blood pressure, lipids, insulin resistance, and inflammation (hsCRP). An earlier Phase 2 trial reported about 23.6% mean weight loss at the higher 8 mg dose by week 36 with no plateau. Hengrui has submitted a marketing application to China's NMPA for chronic weight management, and Kailera began a global Phase 3 program (KAI-9531) evaluating higher maintenance doses (8 mg and 10 mg) and longer treatment by late 2025. HRS9531/KAI-9531 is investigational, is not approved outside of any regulatory review in China, and is not a supplement or research chemical; it is studied only in clinical trials. Weight Management (https://peptrackerpro.com/benefits/weight-management)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Body Composition (https://peptrackerpro.com/benefits/body-composition)Metabolism (https://peptrackerpro.com/benefits/metabolism)+1 more View Details: https://peptrackerpro.com/peptides/hrs9531 \+ Compare: https://peptrackerpro.com/compare?select=hrs9531 Track in App: https://app.peptrackerpro.com/?add=hrs9531 ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Retatrutide", "description": "An investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease.", "url": "https://peptrackerpro.com/peptides/retatrutide", "lastReviewed": "2026-06-13", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "Retatrutide", "item": "https://peptrackerpro.com/peptides/retatrutide" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People following emerging obesity treatment research?", "acceptedAnswer": { "@type": "Answer", "text": "Retatrutide is a research peptide studied in preclinical models. An investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease." } }, { "@type": "Question", "name": "Those interested in triple agonist pharmacology?", "acceptedAnswer": { "@type": "Answer", "text": "Retatrutide is a research peptide studied in preclinical models. An investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease." } }, { "@type": "Question", "name": "Individuals comparing next-generation metabolic peptides?", "acceptedAnswer": { "@type": "Answer", "text": "Retatrutide is a research peptide studied in preclinical models. An investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease." } } ] } ] ```